Tsai Y.-T.Hsiao Y.-J.LI-KAI TSAIYen P.-S.Lin F.-Y.Lu C.-H.Fang C.-W.2021-11-262021-11-2620180022510Xhttps://www.scopus.com/inward/record.uri?eid=2-s2.0-85044143822&doi=10.1016%2fj.jns.2018.03.021&partnerID=40&md5=22821fe14f58e868b680ebfd0e4a5f0fhttps://scholars.lib.ntu.edu.tw/handle/123456789/587984Dabigatran; Hemorrhagic transformation; Idarucizumab; Ischemic stroke; Thrombolysis[SDGs]SDG3alteplase; dabigatran; idarucizumab; antithrombin; dabigatran; idarucizumab; monoclonal antibody; adult; aged; aphasia; atrial fibrillation; brain hemorrhage; brain infarction; brain ischemia; case report; CHA2DS2-VASc score; clinical article; computer assisted tomography; congestive heart failure; female; fibrinolytic therapy; hemiparesis; hemiplegia; human; hypertension; Letter; male; middle aged; middle cerebral artery occlusion; National Institutes of Health Stroke Scale; percutaneous thrombectomy; priority journal; Rankin scale; slurred speech; vomiting; brain hemorrhage; brain ischemia; cerebrovascular accident; diagnostic imaging; fatality; fibrinolytic therapy; Aged; Antibodies, Monoclonal, Humanized; Antithrombins; Brain Ischemia; Dabigatran; Fatal Outcome; Female; Humans; Intracranial Hemorrhages; Male; Middle Aged; Stroke; Thrombolytic Therapyletter10.1016/j.jns.2018.03.021296270122-s2.0-85044143822